CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
Background - This study aims to evaluate antitumor response of palbociclib in patients with advanced chordoma, an ultra-rare cancer without approved systemic therapy. Previous data showed that palbociclib reduced cell viability and proliferation in CDKN2A-deficient chordoma cell lines. - Patients an...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
7 July 2025
|
| In: |
ESMO open
Year: 2025, Jahrgang: 10, Heft: 7, Pages: 1-12 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2025.105498 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2025.105498 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702925013675 
|
| Verfasserangaben: | M.-V. Teleanu, C.E. Heilig, S. Pirmann, R. Hamacher, S. Bauer, V.I. Gaidzik, R. Mayer-Steinacker, J. Al-Sabah, S.S.L. Roldan Pinzon, H. Süße, A. Freitag, P. Horak, S. Kreutzfeldt, B. Hutter, J. Hüllein, O. Sedlaczek, B. Lehner, G. Egerer, D. Jäger, C. Müller-Tidow, D. Hübschmann, C. von Kalle, T.F. E. Barth, S. Fröhling & R.F. Schlenk |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1942064306 | ||
| 003 | DE-627 | ||
| 005 | 20251126080525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251124s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2025.105498 |2 doi | |
| 035 | |a (DE-627)1942064306 | ||
| 035 | |a (DE-599)KXP1942064306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Teleanu, Maria-Veronica |d 1977- |e VerfasserIn |0 (DE-588)1136788557 |0 (DE-627)893574074 |0 (DE-576)49028566X |4 aut | |
| 245 | 1 | 0 | |a CDK4/6 inhibition in advanced chordoma |b final results of the NCT PMO-1601 trial |c M.-V. Teleanu, C.E. Heilig, S. Pirmann, R. Hamacher, S. Bauer, V.I. Gaidzik, R. Mayer-Steinacker, J. Al-Sabah, S.S.L. Roldan Pinzon, H. Süße, A. Freitag, P. Horak, S. Kreutzfeldt, B. Hutter, J. Hüllein, O. Sedlaczek, B. Lehner, G. Egerer, D. Jäger, C. Müller-Tidow, D. Hübschmann, C. von Kalle, T.F. E. Barth, S. Fröhling & R.F. Schlenk |
| 264 | 1 | |c 7 July 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.11.2025 | ||
| 520 | |a Background - This study aims to evaluate antitumor response of palbociclib in patients with advanced chordoma, an ultra-rare cancer without approved systemic therapy. Previous data showed that palbociclib reduced cell viability and proliferation in CDKN2A-deficient chordoma cell lines. - Patients and methods - We conducted a phase II single-arm, open-labeled trial on palbociclib in adult patients with advanced chordomas with p16 (by immunohistochemistry) or CDKN2A (by genomic analysis) loss along with retained CDK4/6 and RB1 expression (by immunohistochemistry or RNA sequencing). Based on CDK4/6/pRB (S780) immunohistochemical expression patterns, a responder versus non-responder signature was assigned. The study used a Simon optimal two-stage design with the primary endpoint of disease control rate (DCR) by RECISTv1.1 after six cycles. Secondary endpoints included progression-free survival, overall survival, and biomarker analysis. The study was considered positive if 25% of patients reached the primary endpoint. - Results - Twenty-eight patients with a median age of 59 years were assessed for the primary endpoint. After a median follow-up of 28 months, the DCR was 39%, with 11 patients achieving stable diseases. No objective responses were obtained. The median progression-free survival was 5.6 months, and the median overall survival was 24.6 months. Treatment was well tolerated without new safety signals. There was no correlation between immunohistochemical responder phenotypes and outcome. Biomarker analysis identified additional clinically actionable alterations affecting PIK3CA, PTEN, MTAP, or MET genes, and druggable pathways by transcriptomic analysis. - Conclusion - Although antitumor activity was modest, the trial met its primary endpoint. Molecularly tailored combination therapies should be considered in the future to improve efficacy. | ||
| 650 | 4 | |a /p16 inactivation | |
| 650 | 4 | |a advanced chordoma | |
| 650 | 4 | |a CDK4/6 inhibition | |
| 650 | 4 | |a multicenter phase II trial | |
| 650 | 4 | |a palbociclib | |
| 700 | 1 | |a Heilig, Christoph E. |d 1981- |e VerfasserIn |0 (DE-588)141951141 |0 (DE-627)632539798 |0 (DE-576)325796440 |4 aut | |
| 700 | 1 | |a Pirmann, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamacher, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bauer, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gaidzik, V. I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayer-Steinacker, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Al-Sabah, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roldan Pinzon, S. S. L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Süße, Heike |e VerfasserIn |0 (DE-588)1279127295 |0 (DE-627)1832408051 |4 aut | |
| 700 | 1 | |a Freitag, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Horak, Peter |e VerfasserIn |0 (DE-588)1156426111 |0 (DE-627)1019252839 |0 (DE-576)502179961 |4 aut | |
| 700 | 1 | |a Kreutzfeldt, Simon |e VerfasserIn |0 (DE-588)1050272064 |0 (DE-627)783733879 |0 (DE-576)404475604 |4 aut | |
| 700 | 1 | |a Hutter, Barbara |e VerfasserIn |0 (DE-588)14009752X |0 (DE-627)61602293X |0 (DE-576)314588760 |4 aut | |
| 700 | 1 | |a Hüllein, Jennifer |e VerfasserIn |0 (DE-588)1096556359 |0 (DE-627)856940941 |0 (DE-576)468079610 |4 aut | |
| 700 | 1 | |a Sedlaczek, Oliver |d 1970- |e VerfasserIn |0 (DE-588)123144493 |0 (DE-627)706179838 |0 (DE-576)293576173 |4 aut | |
| 700 | 1 | |a Lehner, Burkhard |e VerfasserIn |0 (DE-588)1063147808 |0 (DE-627)810647311 |0 (DE-576)420525297 |4 aut | |
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |d 1981- |e VerfasserIn |0 (DE-588)1099133653 |0 (DE-627)858143798 |0 (DE-576)469237082 |4 aut | |
| 700 | 1 | |a Kalle, Christof von |d 1962- |e VerfasserIn |0 (DE-588)1036481115 |0 (DE-627)75107926X |0 (DE-576)168957396 |4 aut | |
| 700 | 1 | |a Barth, Thomas F. E. |d 1963- |e VerfasserIn |0 (DE-588)113514174 |0 (DE-627)493437096 |0 (DE-576)169952088 |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |d 1969- |e VerfasserIn |0 (DE-588)120890046 |0 (DE-627)080950302 |0 (DE-576)188733930 |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 10(2025), 7 vom: Juli, Artikel-ID 105498, Seite 1-12 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a CDK4/6 inhibition in advanced chordoma final results of the NCT PMO-1601 trial |
| 773 | 1 | 8 | |g volume:10 |g year:2025 |g number:7 |g month:07 |g elocationid:105498 |g pages:1-12 |g extent:12 |a CDK4/6 inhibition in advanced chordoma final results of the NCT PMO-1601 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2025.105498 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702925013675 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251124 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 25 |y j | ||
| 998 | |g 120890046 |a Fröhling, Stefan |m 120890046:Fröhling, Stefan |d 50000 |e 50000PF120890046 |k 0/50000/ |p 24 | ||
| 998 | |g 1036481115 |a Kalle, Christof von |m 1036481115:Kalle, Christof von |d 50000 |e 50000PK1036481115 |k 0/50000/ |p 22 | ||
| 998 | |g 1099133653 |a Hübschmann, Daniel |m 1099133653:Hübschmann, Daniel |d 910000 |d 911500 |d 160000 |e 910000PH1099133653 |e 911500PH1099133653 |e 160000PH1099133653 |k 0/910000/ |k 1/910000/911500/ |k 0/160000/ |p 21 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 20 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 50000 |e 50000PJ1032507535 |k 0/50000/ |p 19 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |d 50000 |e 910000PE105502168X |e 910100PE105502168X |e 50000PE105502168X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 18 | ||
| 998 | |g 1063147808 |a Lehner, Burkhard |m 1063147808:Lehner, Burkhard |d 910000 |d 911460 |e 910000PL1063147808 |e 911460PL1063147808 |k 0/910000/ |k 1/910000/911460/ |p 17 | ||
| 998 | |g 123144493 |a Sedlaczek, Oliver |m 123144493:Sedlaczek, Oliver |d 910000 |d 911400 |e 910000PS123144493 |e 911400PS123144493 |k 0/910000/ |k 1/910000/911400/ |p 16 | ||
| 998 | |g 14009752X |a Hutter, Barbara |m 14009752X:Hutter, Barbara |d 50000 |e 50000PH14009752X |k 0/50000/ |p 14 | ||
| 998 | |g 1050272064 |a Kreutzfeldt, Simon |m 1050272064:Kreutzfeldt, Simon |d 50000 |e 50000PK1050272064 |k 0/50000/ |p 13 | ||
| 998 | |g 1156426111 |a Horak, Peter |m 1156426111:Horak, Peter |d 50000 |e 50000PH1156426111 |k 0/50000/ |p 12 | ||
| 998 | |g 1279127295 |a Süße, Heike |m 1279127295:Süße, Heike |d 50000 |e 50000PS1279127295 |k 0/50000/ |p 10 | ||
| 998 | |g 141951141 |a Heilig, Christoph E. |m 141951141:Heilig, Christoph E. |d 50000 |e 50000PH141951141 |k 0/50000/ |p 2 | ||
| 998 | |g 1136788557 |a Teleanu, Maria-Veronica |m 1136788557:Teleanu, Maria-Veronica |d 50000 |e 50000PT1136788557 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1942064306 |e 481181441X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"noteIll":"Diagramme","extent":"12 S."}],"recId":"1942064306","person":[{"display":"Teleanu, Maria-Veronica","given":"Maria-Veronica","role":"aut","family":"Teleanu"},{"display":"Heilig, Christoph E.","family":"Heilig","given":"Christoph E.","role":"aut"},{"display":"Pirmann, S.","role":"aut","given":"S.","family":"Pirmann"},{"role":"aut","given":"R.","family":"Hamacher","display":"Hamacher, R."},{"display":"Bauer, S.","family":"Bauer","role":"aut","given":"S."},{"display":"Gaidzik, V. I.","role":"aut","given":"V. I.","family":"Gaidzik"},{"display":"Mayer-Steinacker, R.","given":"R.","role":"aut","family":"Mayer-Steinacker"},{"display":"Al-Sabah, J.","given":"J.","role":"aut","family":"Al-Sabah"},{"family":"Roldan Pinzon","role":"aut","given":"S. S. L.","display":"Roldan Pinzon, S. S. L."},{"family":"Süße","given":"Heike","role":"aut","display":"Süße, Heike"},{"family":"Freitag","role":"aut","given":"A.","display":"Freitag, A."},{"display":"Horak, Peter","given":"Peter","role":"aut","family":"Horak"},{"display":"Kreutzfeldt, Simon","role":"aut","given":"Simon","family":"Kreutzfeldt"},{"role":"aut","given":"Barbara","family":"Hutter","display":"Hutter, Barbara"},{"display":"Hüllein, Jennifer","role":"aut","given":"Jennifer","family":"Hüllein"},{"family":"Sedlaczek","role":"aut","given":"Oliver","display":"Sedlaczek, Oliver"},{"display":"Lehner, Burkhard","family":"Lehner","given":"Burkhard","role":"aut"},{"given":"Gerlinde","role":"aut","family":"Egerer","display":"Egerer, Gerlinde"},{"family":"Jäger","role":"aut","given":"Dirk","display":"Jäger, Dirk"},{"display":"Müller-Tidow, Carsten","family":"Müller-Tidow","role":"aut","given":"Carsten"},{"display":"Hübschmann, Daniel","family":"Hübschmann","role":"aut","given":"Daniel"},{"role":"aut","given":"Christof von","family":"Kalle","display":"Kalle, Christof von"},{"display":"Barth, Thomas F. E.","family":"Barth","given":"Thomas F. E.","role":"aut"},{"family":"Fröhling","given":"Stefan","role":"aut","display":"Fröhling, Stefan"},{"display":"Schlenk, Richard Friedrich","given":"Richard Friedrich","role":"aut","family":"Schlenk"}],"relHost":[{"origin":[{"publisher":"Elsevier ; BMJ","dateIssuedKey":"2016","publisherPlace":"[London] ; London","dateIssuedDisp":"2016-"}],"title":[{"subtitle":"cancer horizons","title":"ESMO open","title_sort":"ESMO open"}],"note":["Gesehen am 13.06.24"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"84705344X","physDesc":[{"extent":"Online-Ressource"}],"disp":"CDK4/6 inhibition in advanced chordoma final results of the NCT PMO-1601 trialESMO open","pubHistory":["1.2016 -"],"name":{"displayForm":["European Society for Medical Oncology"]},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"part":{"volume":"10","year":"2025","text":"10(2025), 7 vom: Juli, Artikel-ID 105498, Seite 1-12","extent":"12","issue":"7","pages":"1-12"},"id":{"issn":["2059-7029"],"eki":["84705344X"],"zdb":["2844985-X"]}}],"origin":[{"dateIssuedDisp":"7 July 2025","dateIssuedKey":"2025"}],"note":["Gesehen am 24.11.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"title":[{"title_sort":"CDK4/6 inhibition in advanced chordoma","title":"CDK4/6 inhibition in advanced chordoma","subtitle":"final results of the NCT PMO-1601 trial"}],"name":{"displayForm":["M.-V. Teleanu, C.E. Heilig, S. Pirmann, R. Hamacher, S. Bauer, V.I. Gaidzik, R. Mayer-Steinacker, J. Al-Sabah, S.S.L. Roldan Pinzon, H. Süße, A. Freitag, P. Horak, S. Kreutzfeldt, B. Hutter, J. Hüllein, O. Sedlaczek, B. Lehner, G. Egerer, D. Jäger, C. Müller-Tidow, D. Hübschmann, C. von Kalle, T.F. E. Barth, S. Fröhling & R.F. Schlenk"]},"id":{"doi":["10.1016/j.esmoop.2025.105498"],"eki":["1942064306"]}} | ||
| SRT | |a TELEANUMARCDK46INHIB7202 | ||